British journal of haematology
Efficacy and safety of eltrombopag in combination with dexamethasone as first-line treatment in adult patients with newly diagnosed immune thrombocytopenia.
Annaïse J Jauch, Paul Schmidt-Barbo, Christoph Schultheiss, Gerda Silling, Mathias Hänel, Jörg Chromik, Thomas Stauch, Karolin Trautmann-Grill, Roland Repp, Clemens Schulte, Bastian Fleischmann, Manfred Welslau, Martina Stauch, Claudia Quiering, Frank Richter
Published: 202610.1111/bjh.70312
Abstract
Left panel: Scheme of the XPAG-ITP trial. The dexamethasone monotherapy (DEX) arm consisted of DEX 40 mg/day for days 1-4 for one to three cycles every 28 days to a maximum of 12 weeks, cycles 2 + 3 were optional. Patients randomised to eltrombopag c…
Preview only. Read the full abstract at the source